Bicara Therapeutics (BCAX) versus The Competition Head-To-Head Survey

Bicara Therapeutics (NASDAQ:BCAX) is one of 620 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its competitors? We will compare Bicara Therapeutics to similar businesses based on the strength of its profitability, earnings, dividends, risk, institutional ownership, valuation and analyst recommendations.

Profitability

This table compares Bicara Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-21.67%	-20.89%
Bicara Therapeutics Competitors	-1,418.91%	-632.07%	-29.27%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Bicara Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	0	1	8	1	3.00
Bicara Therapeutics Competitors	3695	11498	36259	1028	2.66

Bicara Therapeutics presently has a consensus target price of $32.25, indicating a potential upside of 177.55%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 2,335.37%. Given Bicara Therapeutics’ competitors higher possible upside, analysts clearly believe Bicara Therapeutics has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Bicara Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Bicara Therapeutics	N/A	-$68.00 million	-3.67
Bicara Therapeutics Competitors	$956.97 million	-$43.81 million	-0.62

Bicara Therapeutics’ competitors have higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

51.0% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 15.5% of Bicara Therapeutics shares are held by company insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Bicara Therapeutics beats its competitors on 7 of the 12 factors compared.

About Bicara Therapeutics

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.